Traders should monitor upcoming revenue guidance and clinic adoption metrics; the SWIFT protocol could accelerate commercial growth, especially if payer policies continue to ease. Watch for follow-on studies or additional insurance coverage changes.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 4 $12.45entry
- T+1 · 9mo ago +1.37%α +1.94% · $12.62
- T+5 · 8mo ago +10.60%α +11.94% · $13.77
- T+20 · 8mo ago +9.08%α +13.49% · $13.58
- T+60 · 6mo ago +27.55%α +17.46% · $15.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay released new clinical data demonstrating that its FDA-cleared SWIFT™ accelerated Deep TMS protocol for major depressive disorder achieves comparable remission and response rates to the standard protocol in significantly fewer treatment days, reducing the acute phase from 20 visits to just 6 half-days. The data show an 87.8% response rate and 78.0% remission rate, with median time to remission cut from 28 to 21 days, supporting improved patient access and retention.
Key Facts
- SWIFT™ protocol reduces acute treatment phase from 20 visits over 4 weeks to 6 half-days, a ~70% reduction in clinic visits
- 87.8% response rate and 78.0% remission rate achieved with SWIFT, comparable to standard protocol
- Median time to remission decreased to 21 days vs. 28 days with standard treatment
- 70% of patients no longer had severe quality-of-life impairment; ~60% returned to normal-range functioning
- Evernorth Behavioral Health eliminated prior authorization for Deep TMS, improving payer access
Financial Impact
Potential for significantly increased treatment adoption due to reduced time burden and improved payer access, which could drive higher utilization and revenue over time
Risk Factors
- Commercial adoption may lag despite clinical success due to provider inertia or reimbursement limitations
- Forward-looking statements are subject to risks including regulatory delays, competition, and failure to scale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249244 |
Track record
24 reports on BWAY
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +21.35% at T+20 after the Mar 26, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $10.11 −5.25% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $10.11 −8.84% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $10.11 −8.84% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $10.11 −9.81% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $10.11 −11.63% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $10.11 −15.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $10.11 −15.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $10.11 −15.18% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $10.11 −28.60% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers